27.01.2011 • News

Ranbaxy CEO Omesh Sethi Quits

Ranbaxy Laboratories, India's top drugmaker, said on Thursday its chief financial officer had resigned, the third top official to quit after Japan's Daiichi Sankyo took majority control.

The company, with annual sales of about $1.7 billion, did not give a reason for Omesh Sethi's resignation but said it was effective Jan. 25.

Shares in Ranbaxy, which the market values at about $5 billion, fell as much as 1.7 percent to 554.15 rupees in a subdued Mumbai market.

Sethi's exit comes less than six months after then chief executive Atul Sobti left citing a rift in strategy.

Daiichi had bought the holdings of Chairman and CEO Malvinder Singh and his family in 2008 and later made an open offer, in a deal valued at $5.4 billion, giving the Japanese No.3 drugmaker a launch pad to expand its generic offerings.Singh stepped down from the company in 2009.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read